Project Grant R37CA304810
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $504K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
East Lansing, MI 48824, USA
Similar Awards
- The National Cancer Institute awarded Duke University $1.882 million under the Cancer Biology Research program (CFDA 93.396) on September 23, 2025, to integrate genome-wide association study data with single-cell omics to reveal the cellular effectors of glioblastoma predisposition. Work will be performed in Durham, North Carolina, with a completion date of August 31, 2029. The Cancer Biology Research program funds fundamental information on the cause and nature of cancer, encompassing cancer...
- The National Cancer Institute awarded Regents of the University of Michigan $660,808 on April 7, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate tissue-resident memory T cell responses in melanoma patients and their durability following immunotherapy treatment. The work will examine how tissue-resident memory T cells with high interferon gamma expression (TRM-IFNG), established at the time of primary melanoma diagnosis, are recalled and expanded to mediate...
- The National Institutes of Health National Cancer Institute awarded the Regents of the University of Michigan $571,735 on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396, Assistance Listing R01CA312636). The award funds research into mechanisms by which collagen extracellular matrix disruption potentiates anti-glioma immune responses. The project combines collagen inhibition with immune-stimulatory gene therapy—specifically AD-HSV1-TK to increase tumor antigen release and...
- The National Cancer Institute, a division of the National Institutes of Health under the Department of Health and Human Services, awarded $134,000 to the University of Massachusetts Medical School on September 3, 2026, under the Cancer Biology Research program (CFDA 93.396). The recipient will conduct research employing genetically engineered mouse models to elucidate mechanisms by which loss of CAMK2B (calcium/calmodulin-dependent protein kinase II beta) promotes metastasis and immune...
- The National Cancer Institute, a component of the Department of Health and Human Services, awarded the Regents of the University of Michigan $669,278 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop microbial-based cancer therapeutics engineered to deliver localized immune activation while minimizing systemic toxicity. The research focuses on nonpathogenic, tumor-tropic E. coli engineered to display membrane-anchored cytokines, specifically decoy-resistant...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded $633,089 to The University of Texas MD Anderson Cancer Center on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate a novel cell stress response mechanism in pancreatic ductal adenocarcinoma (PDAC) that enables cancer cells to adapt to adverse microenvironmental conditions and evade immune surveillance. The research will identify and characterize immunotherapeutic...
- The National Institutes of Health National Cancer Institute awarded Michigan State University $157,000 on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop a human pluripotent stem cell-derived preclinical model for NUT carcinoma. NUT carcinoma is an aggressive malignancy predominantly driven by BRD4::NUTM1 fusion genes. The recipient will create human pluripotent stem cell lines engineered to express the BRD4::NUTM1 fusion gene, building on prior work with...
- The National Cancer Institute awarded the Regents of the University of Michigan $646,285 on July 9, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate the role of solute carrier family members in dendritic cell-mediated tumor immunity and immunotherapy response. The project examines how solute carrier (SLC) transporters—a superfamily of over 400 nutrient and metabolite transporters—regulate dendritic cell maturation and function within the tumor microenvironment, with...
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $614,260 on May 11, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate how hypoxia regulates ferroptosis, a form of iron-dependent cell death implicated in cancer suppression. The research examines the oxygen-sensing mechanisms through which hypoxia inhibits ferroptosis independently of the canonical prolyl hydroxylase-von Hippel-Lindau-hypoxia inducible factor pathway, with...
- The National Cancer Institute awarded the University of Virginia $161,500 for cancer cell biology research on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396). The project develops methods to classify pancreatic ductal adenocarcinoma circulating tumor cells by single-cell deformability. Researchers will create a perfusable co-culture system with cancer-associated fibroblasts to generate pancreatic cancer cells expressing varied epithelial and mesenchymal states under shear...